Different lymph node dissection ranges during radical prostatectomy for patients with prostate cancer: a systematic review and network meta-analysis.


Journal

World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544

Informations de publication

Date de publication:
06 Mar 2023
Historique:
received: 13 09 2022
accepted: 11 02 2023
entrez: 5 3 2023
pubmed: 6 3 2023
medline: 8 3 2023
Statut: epublish

Résumé

The purpose of this network meta-analysis was to compare the effectiveness and adverse effects of limited, standard, extended, and super-extended pelvic lymph node dissection (PLND) following radical prostatectomy. This study followed the PRISMA 2020 statement. Clinical trials were searched from three electronic databases, including PubMed, the Cochrane Library, and Embase from the database's inception to April 5, 2022. The lymph node-positive rate, biochemical recurrence-free rate, lymphocele rate, thromboembolic rate, and overall complication rate were compared by meta-analysis. Data analyses were performed using R software based on the Bayesian framework. Sixteen studies involving 15,269 patients were included. All 16 studies compared the lymph node-positive rate; 5 studies compared the biochemical recurrence-free rate; 10 studies compared the lymphocele rate; 6 studies compared the thromboembolic rate, and 9 studies compared the overall complication rate. According to Bayesian analysis, the lymph node-positive rate, lymphocele rate, and overall complication rate were significantly associated with the extension of the PLND range. The limited, extended, and super-extended PLND templates showed a similar but lower biochemical recurrence-free rate and a higher thromboembolic rate than the standard template. The extension of the PLND range is associated with an elevated lymph node-positive rate; however, it does not improve the biochemical recurrence-free rate and correlates with an increased risk of complications, especially lymphocele. The selection of the PLND range in clinical practice should consider the oncological risk and adverse effects. PROSPERO (CRD42022301759).

Identifiants

pubmed: 36872312
doi: 10.1186/s12957-023-02932-y
pii: 10.1186/s12957-023-02932-y
pmc: PMC9987045
doi:

Types de publication

Meta-Analysis Systematic Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

80

Informations de copyright

© 2023. The Author(s).

Références

BJU Int. 2018 May;121(5):725-731
pubmed: 28834085
Scand J Urol Nephrol. 1994 Sep;28(3):273-5
pubmed: 7817169
BJU Int. 2013 Jul;112(1):81-8
pubmed: 23351148
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
J Urol. 2020 Feb;203(2):338-343
pubmed: 31437119
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Eur Urol. 2017 Jul;72(1):84-109
pubmed: 28126351
Urology. 2013 Sep;82(3):653-8
pubmed: 23987158
J Urol. 2018 Mar;199(3):683-690
pubmed: 29203269
J Urol. 2015 Jan;193(1):117-25
pubmed: 25158271
J Laparoendosc Adv Surg Tech A. 2012 Oct;22(8):785-90
pubmed: 22967037
Eur Urol Oncol. 2021 Aug;4(4):532-539
pubmed: 33865797
Eur Urol Oncol. 2018 Oct;1(5):443-448
pubmed: 31158086
Cent European J Urol. 2018;71(3):262-269
pubmed: 30386645
Eur Urol. 2006 Nov;50(5):1006-13
pubmed: 16959399
J Urol. 2003 Jan;169(1):145-7; discussion 147-8
pubmed: 12478123
Urology. 2015 Jun;85(6):1505-9
pubmed: 26099895
J Urol. 2007 Jul;178(1):120-4
pubmed: 17499306
Ann Surg Oncol. 2017 Jul;24(7):2047-2054
pubmed: 28271172
J Urol. 2008 Feb;179(2):408-13
pubmed: 18076938
Eur Urol. 2021 May;79(5):595-604
pubmed: 33293077
J Urol. 1997 Nov;158(5):1891-4
pubmed: 9334624
Eur Urol. 2021 Feb;79(2):243-262
pubmed: 33172724
Eur Urol Oncol. 2021 Apr;4(2):134-149
pubmed: 33745687
BJU Int. 2010 Aug;106(3):391-6
pubmed: 20089113
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Aktuelle Urol. 2010 Jan;41 Suppl 1:S10-4
pubmed: 20094944
J Urol. 2002 Apr;167(4):1681-6
pubmed: 11912387
Minerva Urol Nefrol. 2017 Oct;69(5):475-485
pubmed: 28281741
Int J Clin Oncol. 2018 Jun;23(3):568-575
pubmed: 29230586
BJU Int. 2013 Jul;112(2):216-23
pubmed: 23356436
J Urol. 2004 Nov;172(5 Pt 1):1840-4
pubmed: 15540734

Auteurs

Xianlu Zhang (X)

Department of Urology Surgery, The First Hospital of China Medical University, Shenyang, 110801, China.

Gejun Zhang (G)

Department of Urology Surgery, The First Hospital of China Medical University, Shenyang, 110801, China.

Jianfeng Wang (J)

Department of Urology Surgery, The First Hospital of China Medical University, Shenyang, 110801, China.

Jianbin Bi (J)

Department of Urology Surgery, The First Hospital of China Medical University, Shenyang, 110801, China. jianbinbi@cmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH